FOR LTC & SENIOR CARE INSTITUTIONS · B2B PROGRAMME
Your waiting list is
1,000 people long.
Your beds won't open
until patients improve.
The LTC capacity crisis is not a bed problem. It is a patient turnover problem. When existing residents plateau on inflammation markers, can't meet discharge thresholds, and transfer to hospital at high rates — no number of new beds fixes the waiting list. Healos™ addresses the cellular health of your highest-risk residents, so the beds can move.
1000+
Waiting list per
typical 100-bed
LTC institution
5–7yr
Average Ontario
wait time
(was 2–3 years)
20
High-risk patients
in the Healos™
Trial proposal
100+
Patients per
institution
at contract stage
| ~68% of cardiac residents | On statins — CoQ10 depleted 40–50%. Fatigue prevents rehab completion. |
| ~52% on loop diuretics | K · Mg · Thiamine depleted. Electrolyte-driven arrhythmia and weakness. |
| 40–50% of cardiac patients | Clinical fear of recurrence. Untracked. Multiplies all other risk (×0.4). |
| Complex polypharmacy | 3–6 concurrent medications typical. Drug-nutrient conflicts compound. |
| No GP access (6.5M Canadians) | Residents waiting for LTC often have no regular physician to intercept decline. |
| Healos™ Trial: 20 patients | Targets all five mechanisms simultaneously. 3-month measurable outcome. |
🛡 All protocols pharmacist-reviewed against complex polypharmacy regimens 📋 Monthly H-Index report for every enrolled resident — shareable with clinical team
🔒 HIPAA & PIPEDA · Private Firestore Vault per resident 📊 Contractual inflammation targets — measurable, verifiable outcomes
THE STRUCTURAL CRISIS - THE NUMBERS
The Waiting List Won't Shorten
Until Your Current Residents Get Better.
These are the structural conditions driving the LTC capacity crisis. Healos™ is designed specifically for this gap
— not as wellness, but as a measurable cellular health intervention for your highest-risk residents.
1,000+
Waiting list per 100-bed LTC institution
in many Ontario regions
5–7yr
Current average Ontario LTC wait time — up from 2–3 years
6.5 M
Canadians without a registered family physician (2024)
40 - 50%
CoQ10 depletion in statin patients — the primary energy deficit driving care burden
The mechanism: When LTC residents have unaddressed drug-nutrient depletions, subclinical chronic inflammation, and mitochondrial energy deficits — they do not meet discharge criteria, they transfer to hospital at higher rates, and they require more intensive nursing intervention per day. Each of these outcomes directly lengthens your waiting list and increases your per-resident care cost. Healos™ addresses all three mechanisms simultaneously in a structured, pharmacist-reviewed, monthly-tracked protocol.
THE HEALOS™ LTC TRIAL PROPOSAL
20 high-risk residents. 3 months.
Measurable outcomes before you commit to anything larger.
The Trial is structured to protect your institution. You select the patients. You set the
outcome expectations. We deliver the data. The long-term contract is conditional on
hitting the agreed targets.
The 20-Patient · 3-Month · LTC Trial
Structured to demonstrate measurable outcome before full institutional commitment
WHAT THE TRIAL MEANS FOR EACH DECISION-MAKER
CEO / EXECUTIVE DIRECTOR
ROI & competitive positioning
- Measurable reduction in per-resident nursing intervention frequency
- Inflammation marker improvement documented in clinical record
- First LTC institution in region offering structured cellular health — market differentiation
- Data package for regulatory and board reporting on care quality
DIRECTOR OF CARE (DOC)
Clinical outcomes & care burden
- Monthly H-Index report per resident — clinical picture between physician visits
- hs-CRP and CoQ10 blood panel before/after comparison at Day 91
- Drug-nutrient interaction review flagging unaddressed polypharmacy gaps
- AI-automated daily tracking — near-zero additional nursing workload
DIRECTOR OF FINANCE (DOF)
Cost analysis & contract terms
- Trial cost per resident: substantially below one acute-care transfer event
- Long-term contract pricing: per-resident monthly fee, volume-discounted at 100+ patients
- Administrative cost: near-zero due to AI automation (no additional headcount)
- Contract conditional on agreed inflammation and care-intensity targets being met
We will respond personally within 48 hours · Proposal includes full pricing, target metrics, and contract terms
INSTITUTIONAL ECONOMICS
The economics of the Healos™ institutional model
How the Healos™ Sovereign Node partnership changes the economics of long-term care delivery
— for institutions that integrate it as a structured resident health programme.
Institutional partnership enquiries: Healos™ is building a network of institutional LTC partners across Ontario and Canada. The Trial is the entry point — the long-term contract (average 100+ residents per institution) is what the partnership becomes. Contact us directly for a proposal specific to your institution's size, patient population, and current care metrics.
Healos™ Patient Programmes
Post-Cardiac Stability Does Not Mean No Risk: Why Post-Cardiac Stability Is the Most Critical Window to Protect | Healos™
Healos™ Canada — Integrative cellular recovery for post-cardiac, post-stroke, and ACHD patients.
Ottawa.Toronto.Florida.New York.
SMS & voicemail: 365.909.2567
Ottawa, Ontario, Canada
PATIENT SERVICES
© 2026 Healos™ Canada · NoHeartAttack.com · Ottawa, Ontario Privacy - Terms - Refunds
Healos™ programmes are dietary supplements and integrative wellness services. They are not medical advice, not medical treatment, and not a substitute for professional medical care. Always consult your physician, cardiologist, or pharmacist before starting any new supplement programme. In case of cardiac emergency, call 911 immediately. Healos™ Canada